Table 2.
Next-generation mitochondrial uncouplers
Compound | Target tissue | Model | Dose | Body weight | Food intake | Whole-body energy expenditure | FA oxidation | Liver TAGs | Muscle TAGs | Plasma glucose | Plasma insulin | Insulin sensitivity | Plasma lipids | Adverse side effects | References |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
C12TPP | Systemic | HFD-fed C57BL/6 mice (6 weeks) | 50 μM/kg/day × 16 days | ↓ | ↓ | ↑ | ↑ | ND | ND | ND | ND | ND | ND | None | 202 |
C4R1 | Systemic | HFD-fed C57BL/6 mice (8 weeks) | 12–14, 30 nM/kg/day × 30 days | ↓ | ↓ | ↑ | ↑ | ND | ND | ND | ND | ND | ND | Reduction in lean body mass | 203 |
db/db mice | 50 mg/kg × 4 weeks | - | - | ND | ND | ND | ND | ↓ | - | ↑ | - | None | |||
CZ5 | Systemic (in vitro uncoupling in muscle and adipose tissue) | Chow-fed C57BL/6 mice | 30 mg/kg/day × 30 days | - | ↑ | ↑ | ↑ | ND | ND | - | - | - | ND | None | 205 |
HFD-fed C57BL/6 mice (8 weeks) | 10 mg/kg/day × 5 weeks | ↓ | ↓ | ↑ | ND | - | ↓ | ↓ | ↓ | ↑ | ↓ Cholesterol | None | |||
db/db mice | 150 mg/kg/day × 60 days | - | - | ND | ND | ND | ND | ↓ | - | ND | ND | None | |||
NPP | Liver | HFD-fed C57BL/6 mice (8 weeks) | 125 mg/kg/day × 8 weeks | ↓ | - | ND | ND | ↓ | ND | ↓ | ↓ | ↑ | ND | None | 207 |
T2D rat model | 5 mg/kg/day × 14 days | - | - | ND | ND | ↓ | ND | ↓ | ↓ | ↑ | 4. TAGs | None | |||
CRMP | Liver | HFD-fed SD rats (3 weeks) | 1 mg/kg/day × 5 days | - | - | - | ↑ | ↓ | ↓ | ↓ | ↓ | ↑ | |TAGs | None | 50 |
ZDF rats | 1 mg/kg/day × 14 days | - | ND | ND | ND | ↓ | ↓ | ↓ | ↓ | ↑ | |TAGs | None | |||
MCD-fed rats (8 weeks) | 1 mg/kg/day x× 6 weeks | - | ND | ND | ND | ↓ | ND | ND | ND | ND | ND | None | |||
A-ZIP/F-1 mice | 2 mg/kg/day × 4 weeks | - | - | - | ND | ↓ | ↓ | ↓ | ↓ | ↑ | |TAGs | None | 60 |